Retrospective analysis of patients with hepatocellular carcinoma complicated with human immunodeficiency virus infection after hepatectomy

doi:10.4251/wjgo.v16.i9.3851

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (109)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-7) series.

Item

Count

PDF

HTML

Figures (1-5)

Tables (1-7)

Sum=49

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=52

Publishing Process of This Article

Item

Count

Browse

Download

Sum=6

Sep 15, 2024 (publication date) through Sep 10, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Sep 15, 2024; 16(9): 3851-3864
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3851

Table 1 Clinical data for patients in the surgery group

Indicator	n = 27
Age (years)	60.15 ± 5.90
Gender (Male:female)	24:3
HIV initial diagnosis, n (%)	20 (74.1)
HIV-RNA positive, n (%)	13 (48.1)
MSM, n (%)	18 (66.7)
Received HART after HIV diagnosis	21 (77.8)
HBV, n (%)	21 (77.8)
HCV, n (%)	2 (7.4)
Chronic alcohol consumption, n (%)	11 (40.7)
PS score (0-1:2-3)	16:11
CD4+ cell count < 200 (cell/μL)	15 (55.6)
Child-Pugh score (A:B)	21:6
BCLC staging (0-B:C-D)	10:17
CNLC Staging (Ia-IIa:IIb-IIIa)	18:9
AFP (ng/mL)	249.00 (3.56-2287.42)
ALT (U/L)	31.48 ± 22.39
AST (U/L)	37.44 ± 26.24
TBIL	16.31 ± 9.37
DBIL	5.62 ± 4.15
IBIL	10.68 ± 6.53
Prothrombin time (second)	13.55 ± 2.35
Albumin	36.88 ± 5.36
Hemoglobin	135.11 ± 13.37
White blood cell count (/L)	4.84 ± 1.66
Platelet count (/L)	127.11 ± 91.61
Tumor maximum diameter (mm)	46 (15-130)
Tumor solitary:multiple	10:17
Hepatic encephalopathy (n)	0
Ascites, n (%)	11 (40.7)
Intraoperative blood loss (50-200:300-500)	19: 8
Hepatic artery embolization, n (%)	12 (44.4)
Postoperative recurrence and retreatment, n (%)	12 (44.4)
Postoperative MVI	8 (29.6)
Tumor capsule, n (%)	12 (44.4)
PDL1 positive, n (%)	17 (63.0)

HART: Highly active antiretroviral therapy; HIV: Human immunodeficiency virus; MSM: Men who have sex with men; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; IBIL: Indirect bilirubin; MVI: Microvascular invasion.

Table 2 Clinical data for patients in the nonsurgical group

Indicator	n = 29
Age (years)	60.38 ± 7.49
Gender (Male:female)	23:6
HIV initial diagnosis, n (%)	17 (58.6)
HIV-RNA positive, n (%)	20 (69.0)
MSM, n (%)	14 (48.3)
Received HART after HIV diagnosis	12 (41.4)
HBV, n (%)	21 (72.4)
HCV, n (%)	4 (13.8)
Chronic alcohol consumption, n (%)	11 (37.9)
CD4+ cell count < 200 (cell/μL)	18 (62.1)
Child-Pugh score (A:B)	14:15
BCLC staging (0-B:C-D)	12:17
CNLC Staging (Ia-IIa:IIb-IIIa)	14:15
AFP (ng/mL)	179.01 (1.64-848.74)
ALT (U/L)	23.66 ± 17.51
AST (U/L)	29.00 ± 20.56
TBIL	14.98 ± 6.82
DBIL	4.29 ± 2.49
IBIL	10.96 ± 4.86
Prothrombin time (second)	13.82 ± 2.11
Albumin	34.37 ± 5.43
Hemoglobin	129.55 ± 14.46
White blood cell count (/L)	5.41 ± 3.95
Platelet count (/L)	168.14 ± 73.22
Tumor maximum diameter (mm)	37 (9-115)
Tumor solitary:multiple	13:16
Hepatic encephalopathy (n)	0
Ascites, n (%)	7 (24.1)
PS score (0-1:2-3, cases)	19:10

Table 3 Comparison of clinical parameters between the surgery and non-surgery groups

Clinical parameters	Surgery group	Non-surgery group	P value
Age (years)	60.15 ± 5.90	60.38 ± 7.49	0.223
Gender (male:female)	24:3	23:6	0.472
HBV (positive:negative)	6:21	8:21	0.643
HCV (positive:negative)	2:25	4:25	0.440
CD4+ cell count < 200 (cell/μL)	15 (55.6)	18 (62.1)	0.621
HIV initial diagnosis, n (%)	20 (69.0)	17 (58.6)	0.222
HIV-RNA positive, n (%)	13 (48.1)	20 (69.0)	0.114
Initiation of HART therapy after HIV diagnosis, n (%)	21 (77.8)	12 (41.1)	0.006^a
MSM, n (%)	18 (66.7)	14 (48.3)	0.269
Child-Pugh score (A:B)	21:6	14:15	0.023^a
BCLC stage (0-B:C-D)	10:17	12:17	0.740
CNLC stage (Ia-IIa:IIb-IIIa)	18:9	14:15	0.165
AFP (ng/mL)	249.00 (3.56-2287.42)	179.01 (1.64-848.74)	0.010^a
ALT (U/L)	31.48 ± 22.39	23.66 ± 17.51	0.149
AST (U/L)	37.44 ± 26.24	29.00 ± 20.56	0.184
TBIL	16.31 ± 9.37	14.98 ± 6.82	0.535
DBIL	5.62 ± 4.15	4.29 ± 2.49	0.148
IBIL	10.68 ± 6.53	10.96 ± 4.86	0.859
Prothrombin time (S)	13.55 ± 2.35	13.82 ± 2.11	0.654
Albumin	36.88 ± 5.36	34.37 ± 5.43	0.088
Hemoglobin	135.11 ± 13.37	129.55 ± 14.46	0.142
White blood cell count (/L)	4.84 ± 1.66	5.41 ± 3.95	0.480
Platelet count (/L)	127.11 ± 91.61	168.14 ± 73.22	0.069
Tumor maximum diameter (mm)	46 mm (15-130 mm)	37 mm (9-115 mm)	0.113
Tumor single:multiple	10:17	13:16	0.554
Ascites, n (%)	11 (40.7)	7 (24.1)	0.184
PS score (0-1:2-3)	16:11	19:10	0.629

^aP < 0.05.

Table 4 Single-factor Cox regression analysis of factors influencing overall survival in the surgical group

Indicator	Cases	95%CI	P value
MSM		1.216-9.629	0.020^a
Y	18
N	9
HIV initial diagnosis		1.023-9.643	0.046^a
Y	20
N	7
BCLC staging		3.241-232.007	0.002^a
0-B	10
C-D	17
MVI		1.655-16.822	0.005^a
Y	8
N	19
CD4 cell count < 200 (cell/μL)		1.264-9.031	0.015^a
Y	8
N	19

^aP < 0.05.

Y: Yes; N: No; MSM: Men who have sex with men; HIV: Human immunodeficiency virus; MVI: Microvascular -nvasion.

Table 5 Single-factor Cox regression analysis of factors influencing disease-free survival in the surgical group

Indicator	Cases	95%CI	P value
MSM		1.041-8.787	0.042^a
Y	18
N	9
HIV initial diagnosis		1.024-10.275	0.046^a
Y	20
N	7
BCLC staging		2.671-190.106	0.004^a
0-B	10
C-D	17
MVI		1.616-21.383	0.007^a
Y	8
N	19
CD4 cell count <200 (cell/μL)		1.052-8.614	0.040^a
Y	8
N	19

^aP < 0.05.

Y: Yes; N: No; MSM: Men who have sex with men; HIV: Human immunodeficiency virus; MVI: Microvascular invasion.

Table 6 Multifactor Cox regression analysis of factors influencing overall survival in the surgical group

Factor	B	SE	Wald	P value	Exp(B)	95%CI
HIV initial diagnosis	-2.402	1.606	2.238	0.135	0.091	0.004, 2.106
CD4 cell count < 200 (cell/μL)	-1.116	0.836	1.783	0.182	0.327	0.064, 1.686
BCLC staging	6.482	2.479	6.839	0.009^a	653.193	5.072, 84118.343
MSM	3.534	1.682	4.415	0.036^a	34.252	1.268, 925.153
MVI	0.022	0.606	0.001	0.972	1.022	0.311, 3.352

^aP < 0.05.

HIV: Human immunodeficiency virus; MSM: Men who have sex with men; MVI: Microvascular invasion.

Table 7 Multifactorial Cox regression analysis of factors influencing disease-free survival in the surgical group

Factor	B	SE	Wald	P value	Exp(B)	95%CI
HIV initial diagnosis	-3.770	1.728	4.762	0.029^a	0.023	0.001, 0.681
CD4 cell count < 200 (cell/μL)	-1.699	1.093	2.415	0.120^a	0.183	0.021, 1.558
BCLC staging	8.138	2.841	8.207	0.004^a	3421.835	13.072, 895725.580
MSM	4.366	1.692	6.661	0.010^a	78.746	2.859, 2169.024
MVI	-0.479	0.702	0.464	0.496	0.620	0.156, 2.455

^aP < 0.05.

HIV: Human immunodeficiency virus; MSM: Men who have sex with men; MVI: Microvascular invasion.

Citation: Lu JJ, Yan S, Chen L, Ju LL, Cai WH, Wu JZ. Retrospective analysis of patients with hepatocellular carcinoma complicated with human immunodeficiency virus infection after hepatectomy. World J Gastrointest Oncol 2024; 16(9): 3851-3864
URL: https://www.wjgnet.com/1948-5204/full/v16/i9/3851.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i9.3851